Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    ACP Recommends HIV Screening for All Patients, Regardless of Risk Factors - (DGNews)
    FDA Grants Full Approval of Maraviroc for Treatment-Experienced Patients With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 11/24/2008 - (DGNews)
    Early Antiretroviral Therapy and Mortality among HIV-Infected Infants - (N Engl J Med)
    Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - AIDS and HIV

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Soft Tissue Non-Hodgkin Lymphoma of Shoulder in a HIV Patient: A Report of a Case and Review of the Literature
      HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
      Primary Kaposi Sarcoma of the Subcutaneous Tissue
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      HIV-2 Diagnosis and Quantification in High-Risk Patients

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Investigative Protease Inhibitor TMC114/R Overcomes Resistance in HIV Patients: Presented at ICAAC

      By Ed Susman

      WASHINGTON, DC -- December 22, 2005 -- Researchers said that the investigative protease inhibitor TMC114 boosted with ritonavir (TMC114/r) appears to overcome resistant HIV even among highly treatment-experienced patients.

      Timothy Wilkin, MD, assistant professor of medicine, Weill Medical College of Cornell University, New York, New York, demonstrated that the ability of TMC114/r to allow patients to achieve undetectable viral loads was dose dependent.

      In a presentation here at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), he reported that about 39% of patients receiving the largest dose of TMC114 (600 mg) boosted by 100 mg of ritonavir were able to achieve an undetectable viral load using the 50-copy assay. In comparison, 7% of patients treated with the optimal protease inhibitor selected by the clinicians were able to reach an undetectable viral load. That difference was statistically significant at the P < .001 level, Dr. Wilkin said.

      "In HIV patients with limited treatment options, TMC114/r provided significantly superior virologic response rates and CD4-positive cell increases versus control," Dr. Wilkin said on December 16th.

      "The recommended dose for further clinical development in treatment-experienced patients is 600 mg TMC114 and 100 mg ritonavir twice a day," he said.

      Dr. Wilkin described the interim results of the Performance Of TMC114/r When Evaluated in triple-class-experienced patients with PI Resistance (POWER 2) trial, a 24-week, phase 2b study. In their substudy, his research team scrutinized what happened if patients were also on the fusion inhibitor enfuvertide, the only injectable antiretroviral drug available.

      Among patients who received enfuvertide (Fuzeon) for the first time along with TMC114 at the highest dose twice daily, 64% achieved undetectable levels of HIV at 24 weeks. That compared with 30% of patients who received TMC114/r without the enfuvertide.

      The use of ritonavir to boost the effectiveness of protease inhibitors has become a common therapeutic strategy. A small dose of ritonavir is given concurrently with a second protease inhibitor -- in this case TMC114.

      The goal of boosting protease inhibitors is to pharmacologically enhance exposure to the second protease inhibitor through the inhibition of the enzyme cytochrome P450. Ritonavir boosting results in increased drug levels of the concomitantly administered protease inhibitor.

      In addition to increased efficiency of the main drug, boosting with ritonavir also is associated with a decreased pill burden, added flexibility to the dosing schedule, and removal of fasting restrictions.

      TMC114, being developed by Tibotec of Belgium, which sponsored the POWER 2 trial.


      [Presentation title: TMC114/r Superior to Standard of Care in 3-Class-Experienced Patients: 24-Wks Primary Analysis of the Power 2 Study (C202). Abstract H-413]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send